Navigation Links
Anthony S. Fauci, M.D., on results from the CAPRISA 004 microbicide study
Date:7/19/2010

Today we congratulate the Centre for the AIDS Programme of Research in South Africa (CAPRISA) and the people of South Africa on the positive findings from the CAPRISA 004 microbicide study, which marks a significant milestone both for the microbicide research field and HIV prevention as a whole.

For years, antiretroviral medicines have been effectively used to treat HIV infection. Through the successful conduct of the CAPRISA 004 study, we now have proof that an antiretroviral drug, in this case tenofovir, can be formulated into a vaginal gel that can protect women against HIV infection. Given that women make up the majority of new HIV infections throughout the world this finding is an important step toward empowering an at-risk population with a safe and effective HIV prevention tool.

The CAPRISA 004 study is an exciting scientific achievement that moves us one step forward to gaining another effective tool to prevent HIV infection. However, because no one approach will be appropriate or acceptable to all, we must continue to pursue a range of HIV prevention modalities, including microbicides, PrEP, and vaccines, as we simultaneously pursue scientific strategies designed to bring us closer to finding a cure for HIV/AIDS.

The daunting nature of the HIV/AIDS pandemic makes it clear that no single organization can tackle the problem alone. The CAPRISA 004 study is an excellent example of what researchers, governments, countries, industry, communities and individual study volunteers can accomplish when working together to find public health solutions. NIAID is proud to be among the many partner organizations that provided significant support and resources to establish the infrastructure and training necessary to conduct this landmark clinical trial.

Now we must build upon the CAPRISA research and identify a highly effective and acceptable microbicide for women and other groups at high-risk for HIV infection. The NIAID-sponsored VOICE study (http://www.niaid.nih.gov/news/newsreleases/2009/Pages/VOICE.aspx), which launched last fall and is expected to enroll 5,000 women in four south African countries, will provide additional safety and effectiveness data for a tenofovir-based vaginal gel as an HIV prevention method. The study also will offer some insight as to the gel's acceptability as a product used once a day rather than one that is used before and after sexual intercourse. Additionally, the VOICE study is examining oral antiretroviral tablets (tenofovir alone or tenofovir plus emtricitabine) as an HIV prevention method. This approach is known as pre-exposure prophylaxis, or PrEP. NIAID and other research organizations are exploring PrEP strategies in studies involving a number of at-risk populations with the first results expected early next year.


'/>"/>

Contact: Laura Sivitz Leifman
sivitzl@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. Stanford Who's Who & Anthony Casimano Make Donation to Help Support National Organization, CancerCare
2. Elizabeth Glaser Pediatric AIDS Foundation President and CEO Charles Lyons Welcomes the Appointment of Anthony Lake as New Executive Director of UNICEF
3. ISSA Applauds Cincinnati Trainer Anthony Reed for Dedication to Health Awareness
4. Renowned Psychiatrist, Lyubov Y Gorelik, M.D., is selected to represent New York in The Leading Physicians of the World
5. Gino Tutera, M.D., F.A.C.O.G. Brings SottoPelle Therapy to Middle Tennessee, Opens Practice in Nashville Medical District
6. Joan Miller, M.D., receives 2010 Leadership Award for the Advancement of Women Faculty
7. University of Utah afib specialist, Marcos Daccarett, M.D., wins Young Investigator Award
8. Nationally Known Interventional Neuroradiologist John Pile-Spellman, M.D., Joins Neurological Surgery, P.C.
9. AMA Honors Vice Admiral John Mateczun, M.D., With Top Government Service Award
10. Many False-Positive HIV Test Results for Those in AIDS Vaccine Trials
11. FDA Reviewer Questions Results of Key Avandia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... From April 30 to ... Care Medicine will host industry leaders for the annual spring Convention & Expo, ... the industry adapt to the issues currently affecting urgent care and on-demand healthcare. ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... are conducting a pilot study of ActiGraph’s CentrePoint Data Hub in ... a leading provider of clinical-grade wearable activity and sleep monitoring solutions for the ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular ... has leant his presence to an educational purpose as the host of the “Informed” ... being cancer. In a recent episode, the series focuses on thyroid cancer. , Although ...
(Date:4/27/2017)... ... 2017 , ... Healthcare companies are trying to meet talent shortages and find ... executive resume. , “If you’re a healthcare executive open to new opportunities this year ... as ready as you are for a new job search. I’ve heard from countless ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... Goodcents Deli ... open in the Lincoln, Neb. area this year. , The first new location ... The second location will open at 84th and Northern Lights Drive this fall. And ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 19, 2017 The Mobile X-Ray product segment is ... CAGR during the forecast period Mobile X-Ray segment ... digital mobile X-Ray devices market, which is estimated to be ... at a CAGR of 7% over the forecast period. Mobile ... more than US$ 100 Mn in 2017 over 2016. The ...
(Date:4/19/2017)... 19, 2017 The Global Effective Microorganisms ... 2022 report has covered and analysed the potential of Global ... market size, shares and growth factors. The report identifies and ... opportunities in the global market. ... Browse 152 Tables and Figures, 6 Major Company Profiles, ...
(Date:4/19/2017)... THOUSAND OAKS, Calif. , April 19, 2017 ... premium industrial buildings it is developing at Conejo ... California , to Atara Biotherapeutics, Inc. ... patients with severe and life-threatening diseases that have ... focus on allogeneic T-cell therapies for cancer, autoimmune ...
Breaking Medicine Technology: